AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23848405 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 4)
Number of subjects: 160
Study 21037344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing
Number of subjects: 59
Study 21037344 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement
Number of subjects: 59
Study 18071725 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved skin
Number of subjects: 69
Study 18071725 — intervention group
Group type: COMPARATOR
Intervention: Clinically non-lesional skin
Number of subjects: 69
Study 16875157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (IAWBC)
Number of subjects: 100
Study 16875157 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 100
Study 12694974 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermochoice endometrial thermal ablation
Number of subjects: 50
Study 12694974 — intervention group
Group type: COMPARATOR
Intervention: Mirena LNG-IUS
Number of subjects: 50
Study 10374098 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual culture group (78 cycles)
Number of subjects: 159
Study 10374098 — intervention group
Group type: COMPARATOR
Intervention: Group culture group (81 cycles)
Number of subjects: 159
Study 8914773 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1MN recombinant gp120 (rgp120) vaccine
Number of subjects: 0
Study 8914773 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1MN recombinant gp120 (rgp120) vaccine with HIV‐1IIIB rgp120 vaccine
Number of subjects: 0
Study 2056136 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 29
Study 2056136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6881177 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (intravenous bolus of methylprednisolone followed by an eight-day tapering course of oral methylprednisolone starting at 32 mg twice a day)
Number of subjects: 76
Study 6881177 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 76
Study 29232351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral 2% lidocaine jelly administered via Uro‐Jet, 5 minutes before TUBC.
Number of subjects: 80
Study 29232351 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no analgesia).
Number of subjects: 80
Study 26397935 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 171
Study 26397935 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment HIV‐1 RNA
Number of subjects: 171
Study 26397935 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 171
Study 24055512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure (VAC) therapy
Number of subjects: 20
Study 24055512 — intervention group
Group type: COMPARATOR
Intervention: Alginate (Sorbalgon) therapy
Number of subjects: 20
Study 24055512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VAC and alginate groups
Number of subjects: 20
Study 24055512 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 20
Study 24055512 — intervention group
Group type: COMPARATOR
Intervention: Alginate therapy
Number of subjects: 20
Study 22429343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C plus 10 mg zinc
Number of subjects: 94
Study 22429343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 20001651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 102
Study 20001651 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 102
Study 20001651 — intervention group
Group type: COMPARATOR
Intervention: Montelukast and Fluticasone
Number of subjects: 102
Study 20001651 — intervention group
Group type: COMPARATOR
Intervention: Pre-bronchodilatory FEV1
Number of subjects: 102
Study 20001651 — intervention group
Group type: COMPARATOR
Intervention: Airway reversibility
Number of subjects: 102
Study 19076086 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter randomized trials and novel classes of drugs and interventional catheter technologies
Number of subjects: 0
Study 15919685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (non-anthracycline-based)
Number of subjects: 260
Study 15919685 — intervention group
Group type: EXPERIMENTAL
Intervention: N+ HR- elderly patients
Number of subjects: 260
Study 12663356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) on both quadriceps muscles with a frequency of 45-60 Hz, 12 seconds of stimulation followed by eight seconds recovery for a total of 30 minutes a day, three days a week for six weeks
Number of subjects: 15
Study 10889132 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR(c))
Number of subjects: 1906
Study 10889132 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class
Number of subjects: 1906
Study 10889132 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of angiotensin-converting enzyme inhibitors
Number of subjects: 1906
Study 10889132 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 1906
Study 10889132 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal atrial natriuretic peptide (ANP)
Number of subjects: 1906
Study 8821417 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg body weight)
Number of subjects: 30
Study 8821417 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase without further treatment
Number of subjects: 30
Study 8821417 — intervention group
Group type: COMPARATOR
Intervention: Failed infarct-related artery recanalization
Number of subjects: 30
Study 1431255 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A (100 mg intravenous single dose)
Number of subjects: 82
Study 2861218 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 35
Study 2861218 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 35
Study 2861218 — intervention group
Group type: COMPARATOR
Intervention: pindolol
Number of subjects: 35
Study 2861218 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 35
Study 31050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at doses below 75 mg daily
Number of subjects: 0
Study 31050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants at doses 1/4 of those recommended for atrial fibrillation
Number of subjects: 0
Study 31050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of antithrombotics than currently recommended
Number of subjects: 0
Study 30566498 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAPS programme delivered by trained female youth
Number of subjects: 340
Study 30566498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 340
Study 27619783 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic micturition chart (EMC)
Number of subjects: 29
Study 27619783 — intervention group
Group type: COMPARATOR
Intervention: Pen and paper micturition chart (MC)
Number of subjects: 29
Study 27619783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMC and MC
Number of subjects: 29
Study 24819710 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise protocol of treating pain (SPTP) with acetaminophen, morphine, buprenorphine transdermal patch, and pregabalin for 8 weeks
Number of subjects: 352
Study 24819710 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 352
Study 24819710 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study 22981558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty balloon post-dilation
Number of subjects: 74
Study 22981558 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon post-dilation
Number of subjects: 74
Study 20959429 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN4096BS (olcegepant) 10 mg
Number of subjects: 13
Study 20959429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16984942 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 16984942 — intervention group
Group type: COMPARATOR
Intervention: MTX alone (Control)
Number of subjects: 0
Study 16260986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic plyometric training (APT)
Number of subjects: 19
Study 16260986 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercises (CON)
Number of subjects: 19
Study 10688397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TOBI) for 24 weeks
Number of subjects: 0
Study 10688397 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 9778488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose inhaled fluticasone propionate (250 mcg bd)
Number of subjects: 23
Study 9778488 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study 8105814 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neuroleptic intervention treatment
Number of subjects: 0
Study 8105814 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 0
Study 3536947 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional presternal antibiotic infiltration (2%)
Number of subjects: 100
Study 3536947 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration (control)
Number of subjects: 100
Study 30124723 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% foam (Cal/BD)
Number of subjects: 25
Study 27133971 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal pre-procedural indometacin (100 mg rectal indometacin within 30 min before ERCP)
Number of subjects: 2600
Study 27133971 — intervention group
Group type: COMPARATOR
Intervention: Risk-stratified post-procedural indometacin (only high-risk patients received indometacin immediately after ERCP)
Number of subjects: 2600
Study 27133971 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal pre-procedural indometacin
Number of subjects: 2600
Study 27133971 — intervention group
Group type: COMPARATOR
Intervention: Risk-stratified post-procedural indometacin
Number of subjects: 2600
Study 24184292 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminette®
Number of subjects: 25
Study 24184292 — intervention group
Group type: COMPARATOR
Intervention: No light therapy (after Luminette® use)
Number of subjects: 25
Study 21471500 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives (modest bonuses equal to about 5 percent of a physician's salary)
Number of subjects: 30
Study 21471500 — intervention group
Group type: EXPERIMENTAL
Intervention: System-level incentives (increased compensation to hospitals and across groups of physicians)
Number of subjects: 30
Study 18378381 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 81
Study 18378381 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 81
Study 18378381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 81
Study 18378381 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (Control group)
Number of subjects: 81
Study 16685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic atomization of Shaduolika and dexamethasone
Number of subjects: 84
Study 16685353 — intervention group
Group type: COMPARATOR
Intervention: Niuhuangjiedu tablets (control)
Number of subjects: 84
Study 14533985 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu‐GM‐CSF (125mg/M(2)) injected subcutaneously twice weekly for four weeks
Number of subjects: 31
Study 14533985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 14533985 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu‐GM‐CSF
Number of subjects: 31
Study 10943575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone (30 microg ethinylestradiol and 3 mg drospirenone)
Number of subjects: 900
Study 10943575 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol/desogestrel (150 microg desogestrel)
Number of subjects: 900
Study 10943575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900
Study 10943575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone
Number of subjects: 900
Study 10943575 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol/desogestrel
Number of subjects: 900
Study 9171791 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT angiography (SCTA)
Number of subjects: 30
Study 9171791 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfemoral angiography
Number of subjects: 30
Study 1544778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 20
Study 1544778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1544778 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide 500 mg vs Placebo
Number of subjects: 20
Study 3534203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate (40 mg/kg amoxicillin plus 10 mg/kg clavulanate, total daily doses in three divided doses)
Number of subjects: 68
Study 3534203 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg)
Number of subjects: 68
Study 29896235 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 86
Study 29896235 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion (control)
Number of subjects: 86
Study 27454547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 412
Study 27454547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 412
Study 27454547 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone 20 mg/d
Number of subjects: 412
Study 24977985 — intervention group
Group type: EXPERIMENTAL
Intervention: InflammaDry test with OSDI included
Number of subjects: 237
Study 24977985 — intervention group
Group type: EXPERIMENTAL
Intervention: InflammaDry test without OSDI
Number of subjects: 237
Study 22628033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐HRM assembly
Number of subjects: 39
Study 22628033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐eSleeve
Number of subjects: 39
Study 22628033 — intervention group
Group type: COMPARATOR
Intervention: Standard eSleeve
Number of subjects: 39
Study 20483968 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Number of subjects: 1004
Study 20483968 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1004
Study 18509289 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI category group N (ODI= or <5 events/hour), N=9
Number of subjects: 29
Study 18509289 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI category group A (5<ODI= or <15 events/hour), N=14
Number of subjects: 29
Study 18509289 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI category group B (ODI>15 events/hour), N=6
Number of subjects: 29
Study 20508073 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 1.0 microg/kg
Number of subjects: 0
Study 20508073 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 2.25 microg/kg
Number of subjects: 0
Study 20508073 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 4.5 microg/kg
Number of subjects: 0
Study 20508073 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-fatigue subscale
Number of subjects: 0
Study 16298657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 241
Study 12452404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299V
Number of subjects: 12
Study 12452404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9677810 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 4
Study 9677810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7929868 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of controlled-release metoprolol
Number of subjects: 60
Study 7929868 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of atenolol
Number of subjects: 60
Study 2889495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 46
Study 2889495 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 46
Study 2889495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide and Flupenthixol
Number of subjects: 46
Study 31870605 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus financial incentives
Number of subjects: 360
Study 31870605 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 360
Study 29941478 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 29941478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 27578562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 147
Study 27578562 — intervention group
Group type: COMPARATOR
Intervention: Intravenous labetalol
Number of subjects: 147
Study 23471837 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of increased breastfeeding duration and exclusivity (experimental intervention)
Number of subjects: 17046
Study 23471837 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard breastfeeding practices and policies)
Number of subjects: 17046
Study 23471837 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at age 6.5 years (PROBIT II)
Number of subjects: 17046
Study 23471837 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at age 11.5 years (PROBIT III)
Number of subjects: 17046
Study 22810476 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Number of subjects: 52
Study 22810476 — intervention group
Group type: COMPARATOR
Intervention: Endoanal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Number of subjects: 52
Study 22810476 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal administration
Number of subjects: 52
Study 22810476 — intervention group
Group type: COMPARATOR
Intervention: Endoanal administration
Number of subjects: 52
Study 19955824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in group S (gland <500 mm(3))
Number of subjects: 24
Study 19955824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in group L (gland >=500 mm(3))
Number of subjects: 24
Study 19955824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet for 6 months in both groups S and L
Number of subjects: 24
Study 18237841 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrojugular access
Number of subjects: 600
Study 18237841 — intervention group
Group type: COMPARATOR
Intervention: Ventrojugular access
Number of subjects: 600
Study 18237841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 600
Study 15545508 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2‐specific inhibitors
Number of subjects: 11000000
Study 12854788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-clip mechanism
Number of subjects: 100
Study 12854788 — intervention group
Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 100
Study 10565580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-information preparation condition
Number of subjects: 100
Study 10565580 — intervention group
Group type: COMPARATOR
Intervention: Low-information preparation condition
Number of subjects: 100
Study 8767599 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training + low-dose heparin calcium (12,500 IU/day for 6 months)
Number of subjects: 374
Study 8767599 — intervention group
Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 374
Study 1751265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lignocaine (mean plasma concentration 0.92 micrograms ml‐1)
Number of subjects: 9
Study 1751265 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lignocaine (mean plasma concentration 1.78 micrograms ml‐1)
Number of subjects: 9
Study 1751265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study 1751265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (both doses)
Number of subjects: 9
Study 6284651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam and pivampicillin
Number of subjects: 22
Study 6284651 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 22
Study 31801427 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSi‐Kompetenzförderprogramm
Number of subjects: 412
Study 26362760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with peanut for 12 months
Number of subjects: 33
Study 25321447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial therapy (treatment group)
Number of subjects: 277
Study 25321447 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 277
Study 22633007 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe sole-embedded apparatus for randomly perturbing the stance phase of gait
Number of subjects: 6
Study 20001969 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium) infusion
Number of subjects: 22
Study 18312520 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion injection of rocuronium (I0.6, I0.9)
Number of subjects: 120
Study 18312520 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of rocuronium (B0.6, B0.9)
Number of subjects: 120
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 811
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (various doses)
Number of subjects: 811